Good Products, a provider of Enterprise Content Management (ECM) solutions for the pharmaceutical, biotechnology and medical device industries, and Adlib Software, a producer of server-based document conversion, recognition and publishing software, announced an OEM partnership.
Good Products and Adlib Software Partner to Facilitate Pharmaceutical
Regulatory Submissions
(24 September, 2008) Good Products, a leading provider of Enterprise Content Management (ECM) solutions for the pharmaceutical, biotechnology and medical device industries, and Adlib Software, a leading producer of server-based document conversion, recognition and publishing software, today announced an OEM partnership. This new partnership has been formed to facilitate regulatory submissions in the pharmaceutical industry and will see the integration of Good Products' electronic document management system (eDMS) g-docs with Adlib Software's Express Server centralized PDF rendering tool.
The collaboration between the two industry-leading scientific software providers addresses the need from the pharmaceutical industry for streamlined and compliant regulatory document management. Using the new integrated system, pharmaceutical organizations will be able to store, manage and track regulatory documents and create high quality regulatory submission-ready PDFs with bookmarks and hyperlinks.
g-docs from Good Products offers life sciences organizations an effective, easy-to-use way of managing their documents including tracking document version history, managing approvals, monitoring and recording changes in an audit log. Additionally, g-docs incorporates CoSign, a digital signature solution that allows an individual to digitally sign a document as if they were using ink. CoSign digital signatures have now been upheld in the US court, and are deemed to pass the 'non- repudiation' test as well as being compliant with the FDA's 21 CFR part 11 Guidance. g-docs uses Adlib Express Server to automatically convert different document formats including Microsoft Office, scanned images, engineering drawings and web and image formats to PDF while meeting the requirements of international regulatory bodies, including the FDA. g-docs also uses Adlib to automatically maintain audit, version, reference and distribution tables within the rendered documents, massively saving time and at the push of a button.
Peter Duff, president and CEO, Adlib Software, comments: "Our partnership with Good Products complements the ability to provide compliant document conversion systems to the pharmaceutical industry. The integration of g-docs and Express Server accelerates regulatory submissions and enables organizations to manage documents in a compliant way across the whole lifecycle, from creation to regulatory submission."
"With the increasing standardization of regulatory submissions in an electronic format, and the need to simplify the User experience, both Adlib Software and Good Products recognize the importance of maintaining the consistency and accuracy of electronic documentation from creation to submission," adds Keith Williams, CEO, Good Products. "We are now looking to work together to develop further enhancements and functionality, enabling deeper integration of Good Products and Adlib Software solutions."
For further information on the Good Products portfolio of document management systems, please visit www.goodproductsEU.com or email info@goodproductsEU.com.
For further information on Adlib Software, please visit www.adlibsoftware.com or email info@adlibsoftware.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.